[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351856-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351856-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","uptake-in-thyroid-tripterygium-glycosides-enhances-radioiodine-cancer-by-promoting-the-expression-and-function-of-nis","Uptake in thyroid Tripterygium glycosides - enhances radioiodine cancer by promoting the expression and function of NIS","","The sodium-iodide symporter (NIS) dysfunction underlies failure of radioiodine (RAI) therapy in advanced thyroid cancer, spanning from suppressed NIS expression driven by oncogenic signaling to complete loss in dedifferentiated disease. Tripterygium glycosides (TG), a natural MAPK-inhibitory compound, was tested in thyroid cancer models with intrinsically low NIS. TG increased iodide uptake, boosted NIS protein, inhibited ERK1/2 signaling, and promoted functional membrane localization by coordinating NIS transcription and destabilizing the NIS-LARG complex. TG plus 131I enhanced intratumoral iodine retention and suppressed tumors versus 131I alone, supporting TG as a preclinical redifferentiation candidate.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/uptake-in-thyroid-tripterygium-glycosides-enhances-radioiodine-cancer-by-promoting-the-expression-and-function-of-nis/351856/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/uptake-in-thyroid-tripterygium-glycosides-enhances-radioiodine-cancer-by-promoting-the-expression-and-function-of-nis/351856.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does radioiodine therapy fail in advanced thyroid cancer?","Question",{"text":63,"@type":64},"Failure is strongly linked to dysfunction of the sodium-iodide symporter (NIS), which ranges from intrinsically suppressed NIS expression to complete loss in dedifferentiated disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the main goal of testing Tripterygium glycosides (TG)?",{"text":68,"@type":64},"To determine whether TG could reactivate NIS function and improve RAI efficacy in preclinical models that show intrinsically low NIS expression associated with early RAI resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How does TG affect NIS activity at the molecular level?",{"text":72,"@type":64},"TG inhibits the ERK1/2 signaling pathway, promotes NIS transcription, destabilizes the NIS-LARG protein complex, and synergistically enhances functional membrane localization of NIS.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351856,1790227763,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nUptake in thyroid Tripterygium glycosides, enhances radioiodine cancer by promoting the expression and function of NIS  \nZhangguo Ying1, Wangang Gong2,3, Mengmeng Shi4, Yujie Chen4 & Yalan Dai2􀀍 The dysfunction of the sodium-iodide symporter (NIS) is a key contributor to radioiodine (RAI)  \ntreatment failure in advanced thyroid cancer. This dysfunction exists on a spectrum, ranging from intrinsically suppressed NIS expression—often driven by constitutive oncogenic signaling—to its complete loss in dedifferentiated disease. While MAPK pathway inhibitors represent a promising redifferentiation strategy, their clinical utility is constrained by variable efficacy and toxicity. This study aimed to investigate the potential of Tripterygium Glycosides (TG), a natural compound with known MAPK-inhibitory activity, to reactivate NIS function in preclinical models characterized by intrinsically low NIS expression, representing an early stage in the continuum of RAI resistance. This study utilized thyroid cancer cell lines with intrinsically low NIS expression. In vitroassays evaluated the effects ofTGon iodide uptake, NIS expression and membrane localization, its interaction with the scaffold protein LARG, and the role of the ERK1/2 signaling pathway. In thyroid cancer mouse xenograft model, the effects ofTG alone or in combination with 131I on intratumoral iodine retention and tumor growth were assessed. TG treatment dose-dependently enhanced iodide uptake and increased total NIS protein levels. Mechanistically, TG inhibited the ERK1/2 signaling pathway. This inhibition promoted NIS transcription while concurrently destabilizing the NIS-LARG protein complex, synergistically facilitating the functional membrane localization of NIS. In animal studies, the combination of TG and 131I significantly enhanced intratumoral iodine retention and suppressed tumor growth compared to 131I monotherapy. This study demonstrates that TG can effectively restore NIS function and enhance RAI efficacy in thyroid cancer models with MAPK pathway hyperactivation and intrinsic NIS suppression. Its action is mediated through the dual regulation of NIS transcription and membrane localization following MAPK/ERK pathway inhibition. These findings provide preclinical proof-ofconcept forTG as a potential redifferentiating agent targeting thyroid cancers with MAPK-driven intrinsic NIS suppression and establish a mechanistic rationale. Future studies in more advanced, dedifferentiated models (e.g., anaplastic thyroid cancer) are warranted to evaluate the broader applicability of this approach across the RAI-resistance spectrum.  \nKeywords Iodine-refractory thyroid cancer, Tripterygium glycosides TG, Sodium-iodide symporter (NIS)  \nThyroid cancer remains the most common endocrine malignancy worldwide. According to the GLOBOCAN 2022 data released by the World Health Organization’s International Agency for Research on Cancer (IARC) in 2024, there were approximately 821,000 new cases of thyroid cancer globally in 2022, ranking it as the seventh most common cancer worldwide by incidence. The disease shows significant geographic variation, with the highest incidence rates observed in East Asia and North America. China alone accounted for an estimated  \n466,000 new cases, representing over half of the global burden1. Data from 2025 estimates that the number of new cases globally approached 850,000 in 2024. In terms of incidence rate, the estimated age-standardized rate (ASR) for 2024 was 9.1 cases per 100,000 population2,3. Current standard management—total thyroidectomy4,5, radioactive iodine (131I) ablation, and TSH suppression—achieves prolonged survival and improved prognosis in approximately 90% of patients6. However, 15–30% of patients with advanced DTC ultimately develop treatment resistance, manifesting as local recurrence (20%) or distant metastasis (10%) . Among these progressing cases, ","cbCail4SvxkUPp6h","https://ap.wps.com/l/cbCail4SvxkUPp6h","pdf",3851068,15,"English","# Background and rationale\n# Study aims and experimental design\n## In vitro assays\n## In vivo xenograft assessment\n# Mechanistic findings\n# Therapeutic outcomes with TG and 131I\n# Conclusions and future directions","[{\"question\":\"Why does radioiodine therapy fail in advanced thyroid cancer?\",\"answer\":\"Failure is strongly linked to dysfunction of the sodium-iodide symporter (NIS), which ranges from intrinsically suppressed NIS expression to complete loss in dedifferentiated disease.\"},{\"question\":\"What was the main goal of testing Tripterygium glycosides (TG)?\",\"answer\":\"To determine whether TG could reactivate NIS function and improve RAI efficacy in preclinical models that show intrinsically low NIS expression associated with early RAI resistance.\"},{\"question\":\"How does TG affect NIS activity at the molecular level?\",\"answer\":\"TG inhibits the ERK1/2 signaling pathway, promotes NIS transcription, destabilizes the NIS-LARG protein complex, and synergistically enhances functional membrane localization of NIS.\"}]","Uptake in thyroid Tripterygium glycosides - enhances radioiodine cancer by promoting the expression and function of NIS | PDF",1790096332,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/787d3c9aeb3d7cff9f1cef1bfd8f83f8.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a748574df4b997f7f7efe64f5dd2d42.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aeadff28612478aba0fcd1e847f63b3a.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bec3e09ec4834f32a03ac442b89e079d.webp",980,1287]